Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
19.41
+0.67 (3.58%)
Sep 30, 2026, 3:00 PM CST
SHA:600645 Revenue
Vcanbio Cell & Gene Engineering Corp., had revenue of 342.03M CNY in the quarter ending June 30, 2026, a decrease of -6.44%. This brings the company's revenue in the last twelve months to 1.40B, down -6.77% year-over-year. In the year 2025, Vcanbio Cell & Gene Engineering Corp., had annual revenue of 1.45B, down -8.23%.
Revenue (ttm)
1.40B
Revenue Growth
-6.77%
P/S Ratio
6.33
Revenue / Employee
722.46K
Employees
1,935
Market Cap
8.85B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.45B | -130.47M | -8.23% |
| Dec 31, 2024 | 1.59B | -4.30M | -0.27% |
| Dec 31, 2023 | 1.59B | 34.84M | 2.24% |
| Dec 31, 2022 | 1.55B | 19.56M | 1.27% |
| Dec 31, 2021 | 1.54B | 216.43M | 16.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pacific Shuanglin Bio-pharmacy | 2.48B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.03B |
| Aurisco Pharmaceutical | 1.70B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Liaoning Chengda Biotechnology | 1.36B |
| Chengdu Easton Biopharmaceuticals | 1.34B |
| Bio-Thera Solutions | 1.01B |
| Daan Gene | 746.91M |